Meningitis - Pipeline Review, H2 2016

Description: Meningitis - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H2 2016, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening. Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis. Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximately 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If none of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely. Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby's head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis.

Report Highlights:

The Pharmaceutical and Healthcare latest pipeline guide Meningitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease).

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction

Meningitis Overview

Therapeutics Development

Pipeline Products for Meningitis - Overview

Pipeline Products for Meningitis - Comparative Analysis

Meningitis - Therapeutics under Development by Companies

Meningitis - Therapeutics under Investigation by Universities/Institutes

Meningitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Meningitis - Products under Development by Companies

Meningitis - Products under Investigation by Universities/Institutes

Meningitis - Companies Involved in Therapeutics Development
Adenium Biotech ApS
Amplyx Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Chongqing Zhifei Biological Products Co Ltd
ContraFect Corp
LG Life Science LTD
Matinas BioPharma Holdings Inc
Sanofi Pasteur SA
Viamet Pharmaceuticals Inc
Meningitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Eupenta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meropenem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal [serotype 4, 6A] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pkh2-02 for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcus pneumonia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tuberculous meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meningitis - Dormant Projects
Featured News & Press Releases

Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated

Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis

Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis

Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine

Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015

Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta

Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Meningitis, H2 2016

Number of Products under Development for Meningitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Meningitis - Pipeline by Adenium Biotech ApS, H2 2016

Meningitis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2016

Meningitis - Pipeline by Chiesi Farmaceutici SpA, H2 2016
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2016
Meningitis - Pipeline by ContraFect Corp, H2 2016
Meningitis - Pipeline by LG Life Science LTD, H2 2016
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H2 2016
Meningitis - Pipeline by Sanofi Pasteur SA, H2 2016
Meningitis - Pipeline by Viamet Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Meningitis - Dormant Projects, H2 2016
Meningitis - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Meningitis, H2 2016
Number of Products under Development for Meningitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Ordering:  
Order Online - http://www.researchandmarkets.com/reports/4015284/  
Order by Fax - using the form below  
Order by Post - print the order form below and send to  

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Meningitis - Pipeline Review, H2 2016
- Web Address: http://www.researchandmarkets.com/reports/4015284/
- Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Site License</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

- Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
- First Name: ___________________________ Last Name: ___________________________
- Email Address: * ___________________________
- Job Title: ___________________________
- Organisation: ___________________________
- Address: ___________________________
- City: ___________________________
- Postal / Zip Code: ___________________________
- Country: ___________________________
- Phone Number: ___________________________
- Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World